Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development.
Neural tube defects (NTDs) are prevalent human birth defects. Mitogen-activated protein kinases (MAPKs), such as c-Jun N-terminal kinase (JNK), are implicated in facilitating neural tube closure, yet upstream regulators remain to be identified. Here, we show that MAP kinase kinase kinase 4 (MEKK4) is strongly expressed in the developing neuroepithelium. Mice deficient in MEKK4 develop highly penetrant NTDs that cannot be rescued by supplementation with folic acid or inositol. Unlike most mouse models of NTDs, MEKK4 mutant embryos display genetically co-segregated exencephaly and spina bifida, recapitulating the phenotypes observed in human patients. To identify downstream targets of MEKK4 during neural tube development, we examined the activity of MAP kinase kinase 4 (MKK4), a signaling intermediate between MAP kinase kinase kinase and JNK/p38. We found a significant reduction in MKK4 activity in MEKK4-deficient neuroepithelium at sites of neural tube closure. MAPK pathways are key regulators of cell apoptosis and proliferation. Analyses of the neuroepithelium in MEKK4-deficient embryos showed massively elevated apoptosis before and during neural tube closure, suggesting an antiapoptotic role for MEKK4 during development. In contrast, proliferation of MEKK4-deficient neuroepithelial cells appeared to be largely unaffected. MEKK4 therefore plays a critical role in regulating MKK4 activity and apoptotic cell death during neural tube development. Disruption of this signaling pathway may be clinically relevant to folate-resistant human NTDs.
Chi
Hongbo
H
Section of Immunobiology, Department of Neurobiology and Kavli Institute of Neuroscience, and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520, USA.
Sarkisian
Matthew R
MR
Rakic
Pasko
P
Flavell
Richard A
RA
D000818:Animals; D017209:Apoptosis; D001921:Brain / Q000002:abnormalities; D048670:MAP Kinase Kinase 4 / Q000378:metabolism; D048768:MAP Kinase Kinase Kinase 4 / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D048055:Mitogen-Activated Protein Kinase 8 / Q000378:metabolism; D009436:Neural Tube Defects / Q000209:etiology*
D048055:Mitogen-Activated Protein Kinase 8; D048768:MAP Kinase Kinase Kinase 4; D048670:MAP Kinase Kinase 4; C482562:Map2k4 protein, mouse
Mech Dev. 1999 Dec;89(1-2):115-24
10559486
Hum Mol Genet. 2000 Apr 12;9(6):993-1000
10767323
Ment Retard Dev Disabil Res Rev. 2000;6(1):6-14
10899792
Cell. 2000 Oct 13;103(2):239-52
11057897
Physiol Rev. 2001 Apr;81(2):807-69
11274345
Teratology. 2002 Feb;65(2):63-9
11857507
Genes Dev. 2002 Mar 15;16(6):676-80
11914272
Nat Rev Genet. 2003 Oct;4(10):784-93
13679871
EMBO J. 2004 Apr 7;23(7):1576-86
15044949
Lancet. 1991 Jul 20;338(8760):131-7
1677062
Science. 1995 Feb 3;267(5198):682-5
7839144
Nat Med. 1997 Jan;3(1):60-6
8986742
J Biol Chem. 1997 Mar 28;272(13):8288-95
9079650
Diabetes. 1997 Jul;46(7):1189-97
9200655
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6881-6
9618507
Cell. 1998 Aug 7;94(3):325-37
9708735
Cell. 1998 Aug 7;94(3):339-52
9708736
Cell. 1998 Nov 13;95(4):521-30
9827804
Development. 1999 Feb;126(3):505-16
9876179
Neuron. 1999 Apr;22(4):667-76
10230788
Nat Genet. 1999 Oct;23(2):176-84
10508513